DA Davidson Initiates Cellebrite (CLBT) at Buy, Sees Understated TAM

Cellebrite DI Ltd. (NASDAQ:CLBT) picked up a Buy rating and a $20 price target from DA Davidson on May 27. The firm argued the digital forensics company's total addressable market is large and growing, and likely understated by the broader Street.

The initiation arrived two weeks after Cellebrite reported first-quarter results that beat consensus. Revenue hit $128.3 million, up 19% from a year earlier. Subscription revenue, the core of the model, rose 23% to $117.9 million. Annualized recurring revenue reached $493 million, a 21% increase.

DA Davidson pointed to multiple drivers for continued wallet share gains – among them a guided acceleration in organic ARR growth. The analyst said that acceleration, paired with a TAM that may be larger than most models assume, justifies the bullish call.

Needham also reiterated a Buy rating on May 15, though it trimmed its price target to $15 from $18. The firm said Cellebrite's first-quarter results outperformed consensus across every line item. The target cut reflected a compressed valuation multiple in the stock, not a deterioration in fundamentals.

Management guided for full-year 2026 revenue between $565 million and $571 million, with ARR expected to land between $567 million and $573 million. Those figures imply continued momentum in the subscription base, which now accounts for the vast majority of total revenue.

Cellebrite builds software for legally sanctioned investigations – digital forensics tools, evidence management platforms, and mobile vulnerability research. Its customer base includes federal agencies and local law enforcement. The company also provides training and certification services.

DA Davidson's $20 target implies roughly 56% upside from the stock's level before the initiation. Whether that upside materializes will depend on Cellebrite's ability to sustain ARR growth above 20% and expand the subscription mix, both of which are already in the guidance.